Related Experiment Video
Updated: Jan 20, 2026

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
Published on: October 31, 2012
Acute Graft-Versus-Host Disease: A Brief Review
Elifcan Aladağ1, Engin Kelkitli2, Hakan Göker1
1Hacettepe University Faculty of Medicine, Department of Hematology, Ankara, Turkey
Abstract:
Graft‐versus‐host disease (GvHD) is an important complication that can be observed after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Acute GvHD (aGvHD) is seen after allo-HSCT and the incidence of aGvHD is around 30%-50%. aGvHD prophylaxis is essential in patients undergoing allo-HSCT. Initial therapy for aGvHD is steroids. Prognosis is poor in aGvHD patients not responding to steroids. In this article, the pathobiology, clinical findings, prophylaxis, and treatment of aGvHD will be summarized.
More Related Videos
Related Concept Videos
09:00High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
09:50Induction of Intestinal Graft-versus-host Disease and Its Mini-endoscopic Assessment in Live Mice
08:05Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
05:54Induction of Graft Versus Host Disease in Mouse Models via Allogeneic Bone Marrow and Splenic Cell Transplantation
08:50Establishment and Evaluation of a Porcine Vein Graft Disease Model
04:23A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

